Instrument Inactif

Communiqués AKOUOS

Actions

AKUS

US00973J1016

Recherche biotechnologique et médicale

Communiqués

01/12/22	AKOUOS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
30/11/22	Lilly and Akouos Announce Expiration of Akouos Tender Offer	PR
14/11/22	AKOUOS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
14/11/22	AKOUOS, INC. : Results of Operations and Financial Condition (form 8-K)	AQ
14/11/22	Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights	AQ
19/10/22	AKOUOS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akouos, Inc. - AKUS	BU
18/10/22	AKOUOS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
18/10/22	Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss	PR
13/09/22	Akouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing Loss	AQ
15/08/22	AKOUOS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
15/08/22	Akouos : Reports Second Quarter 2022 Financial Results and Provides Business Highlights - Form 8-K	PU
15/08/22	AKOUOS, INC. : Results of Operations and Financial Condition (form 8-K)	AQ
15/08/22	Akouos Reports Second Quarter 2022 Financial Results and Provides Business Highlights	AQ
26/07/22	AKOUOS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
27/06/22	AKOUOS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
19/05/22	Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting	AQ
12/05/22	AKOUOS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
12/05/22	AKOUOS, INC. : Results of Operations and Financial Condition (form 8-K)	AQ
12/05/22	Akouos Reports First Quarter 2022 Financial Results and Provides Business Highlights	AQ
04/05/22	Akouos to Present at Bank of America 2022 Healthcare Conference	AQ
03/05/22	Akouos to Present at the American Society of Gene and Cell Therapy 25th Annual Meeting	AQ
29/03/22	AKOUOS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
29/03/22	Akouos : Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights - Form 8-K	PU
29/03/22	AKOUOS, INC. : Results of Operations and Financial Condition (form 8-K)	AQ
29/03/22	Akouos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights	AQ